Biocomposites exceeds revenue expectations and takes a big step forward in its research and development

Biocomposites United Kingdom United States of America

New record for sales growth and number of patients supportedProduct portfolio enhanced through acquisition of NanoBone® and expansion of STIMULAN® approval as an antibiotic carrier to treat bacterial infectionResearch and Development boosts with STIMULAN VG moving to phase II clinical trial and investment in RenoviteView original content:https://www.prnewswire.co.uk/news-releases/biocomposites-exceeds-revenue-expectations-and-takes-a-big-step-forward-in-its-research-and-development-302012661.html